arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Entrada Therapeutics, Inc.

TRDA

$6.50 ▼ -0.21 (-3.06%) at close

27 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Entrada Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $274.4M

Dividend Yield —

Revenue Growth -53.9% ↗

Op. Margin None

ROIC -15.2% ↘

FCF / Share $-0.77 ↗

Trailing P/E —

Price / Book 1.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$898.00K

↓ -53.9% —

Net Income Profit after all expenses

$-39.72M

↓ -128.9% —

Operating Margin Operating profit as % of sales

-106.0%

↓ -575.6% —

FCF / Share Free cash flow per share

$-0.77

↑ +22.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-53.9% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-774%)	-95.7% Weak → Weak Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1297%)	-96.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1307%)	-91.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1247%)	-97.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1324%)	-65.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-915%)	-10.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-233%)	-55.3% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-791%)	421.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5164%)	134.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1576%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	2.9% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-126.2% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3033.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-202.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	89.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	N/M	62.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	-5.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	69.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	91.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	90.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	89.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-59.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-128.9% Weak Weak Year-over-year change in net income	-128.9% Weak Weak Year-over-year change in net income	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	61.2% Excellent ↓ Excellent Declining Year-over-year change in net income	69.2% Excellent ↑ Excellent Improving Year-over-year change in net income	69.2% Excellent ↑ Excellent Improving Year-over-year change in net income	69.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-33.5% Weak ↑ Weak Improving Year-over-year change in net income	-158.6% Weak ↓ Weak Declining Year-over-year change in net income	-158.6% Weak ↓ Weak Declining Year-over-year change in net income	-158.6% Weak ↓ Weak Declining Year-over-year change in net income	-112.7% Weak Weak Year-over-year change in net income	-78.8% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	—	-3.3% Weak Weak Year-over-year change in free cash flow	—	—	—	-22.7% Weak Weak Year-over-year change in free cash flow	—	—	—	N/M	—	—	—	N/M	—	—	91.7% Excellent Excellent Year-over-year change in free cash flow	90.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-63.3% Weak Weak Compound annual revenue growth over 3 years	-67.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-106.0% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-807%)	-15.7% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-205%)	-110.7% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-838%)	56.4% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+276%)	35.7% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+138%)	11.7% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-22%)	32.0% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+114%)	-89.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-698%)	-22.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-253%)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	-84.4% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-803%)	3.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-75%)	—	24.8% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+107%)	39.7% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+231%)	-22.8% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-290%)	-15.3% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-227%)	-36.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-406%)	-26.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-320%)	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	-192.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-86.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-44.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-11.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.64x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	—	2.29x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	-28.51x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	-1.12x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	-30.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.14x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.31x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	—	1.13x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-15.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-1.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.8% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	6.2% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	1.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	4.5% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-2.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-9.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	15.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	13.3% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	13.3% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	16.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	16.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-15.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-1.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-3.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	9.2% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	4.1% Caution ↑ Caution Improving Operating profit relative to total assets Optimal: > 10%	1.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	2.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-3.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-1.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-7.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-19.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-17.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	-14.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-198%)	-12.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	-5.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-134%)	-4.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-130%)	-4.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	0.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-98%)	5.6% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-63%)	5.5% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-64%)	8.7% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-42%)	-3.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-126%)	-2.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-118%)	-3.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-122%)	-2.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-119%)	-11.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-9.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-8.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-156%)	-7.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-152%)	-6.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-141%)	11.5% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-23%)	14.2% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-5%)	16.9% Good → Good Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+12%)	20.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+39%)	14.2% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-5%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-99.28M	$-76.44M	$-90.39M	$-93.29M	$-72.48M	$-67.84M	$-101.21M	$-78.05M	$-185.25M	$-68.44M	$-67.60M	$-51.88M	$-79.74M	$-227.65M	$-45.16M	—	—	$-84.64M	$-291.06M	$-122.17M	—	—	$-39.05M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.02	$0.02	—	$0.04	$0.05	$0.50	—	$0.48	$2.77	$1.76	—	$1.31	$0.55	$0.78	—	$0.00	$0.00	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.01	$-0.95	$-0.94	$-1.06	$-1.04	$-0.42	$-0.03	$-0.35	$1.61	$0.70	$-0.29	$1.07	$-0.78	$-0.21	$-0.78	$-0.80	$-0.74	$-0.69	$16.02	$-9.78	$-7.56	$-6.67	$-7.45	$-6.13	—	—	—
Free Cash Flow per Share (USD)	$-0.77	$-1.00	—	$-0.69	—	$-0.97	—	—	—	$-0.79	—	—	—	$6.23	—	$-0.90	$-0.60	$-0.69	—	—	$-7.22	$-7.36	—	—	—	—	—
Book Value per Share (USD)	$5.99	$6.98	$8.00	$8.91	$9.98	$11.00	$11.41	$11.30	$11.57	$8.02	$7.25	$7.40	$6.23	$6.93	$6.77	$7.45	$8.19	$8.87	$9.57	$-46.90	$-45.06	$-39.53	$-33.35	$-29.00	—	—	—
Tangible Book Value per Share (USD)	$5.99	$6.98	$8.00	$8.91	$9.98	$11.00	$11.41	$11.30	$11.57	$8.02	$7.25	$7.40	$6.23	$6.93	$6.77	$7.45	$8.19	$8.87	$9.57	$-46.90	$-45.06	$-39.53	$-33.35	$-29.00	—	—	—
Basic Weighted Avg Shares (shares)	42.22M	41.84M	—	41.46M	41.34M	41.07M	—	40.63M	34.18M	33.50M	—	33.28M	33.16M	32.37M	—	31.30M	31.28M	31.25M	—	1.48M	1.31M	1.26M	—	1.14M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$211.33M	$247.68M	$281.80M	$314.24M	$349.34M	$384.76M	$400.56M	$394.73M	$403.73M	$240.23M	$210.97M	$217.61M	$264.25M	$286.54M	$187.90M	—	—	$257.29M	$291.98M	$116.37M	—	—	$36.59M	—	—	—	—
Total Equity (USD)	$233.41M	$270.85M	$306.13M	$340.72M	$379.50M	$417.26M	$428.68M	$422.45M	$429.93M	$269.37M	$242.36M	$246.66M	$206.91M	$229.61M	$212.55M	$233.22M	$256.04M	$277.39M	$298.72M	$-72.59M	$-59.01M	$-49.67M	$-41.49M	$-33.05M	$-26.14M	$-20.12M	$-15.52M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$898.00K	$875.00K	$1.30M	$1.61M	$1.95M	$20.56M	$37.40M	$19.57M	$94.69M	$59.12M	$41.85M	$43.73M	$18.17M	$25.26M	—	$0.00	$0.00	—	—	—	—	—	—	—	—	—	—
Depreciation Expense (USD)	$800.00K	$805.00K	$886.00K	$1.20M	$1.10M	$946.00K	$992.00K	$900.00K	$900.00K	$934.00K	$736.00K	$800.00K	$700.00K	$541.00K	$526.00K	$500.00K	$500.00K	$390.00K	$364.00K	$300.00K	$300.00K	$199.00K	$98.00K	$100.00K	—	—	—
Net Income, GAAP (USD)	$-39.72M	$-39.72M	$-39.16M	$-17.35M	$-17.35M	$-17.35M	$1.13M	$23.50M	$23.50M	$23.50M	$-9.54M	$-6.67M	$-6.67M	$-6.67M	$-24.63M	$-21.67M	$-21.67M	$-21.67M	$-18.45M	$-8.38M	$-8.38M	$-8.38M	$-8.67M	$-4.69M	—	—	—
Operating Cash Flow (USD)	$-32.46M	$-41.70M	$-32.20M	$-28.31M	—	$-38.51M	$-31.61M	—	—	$-25.52M	$-4.01M	—	—	$203.40M	$-27.30M	$-27.48M	$-18.01M	$-20.99M	$-20.54M	—	$-7.91M	$-8.34M	$-6.62M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Entrada Therapeutics, Inc.

Analytical Summary

27-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TRDA with peers